Cellarity is a pioneering brand in the field of therapeutics, aiming to revolutionize drug discovery by studying and altering the cellular signatures of disease. Founded in December 2019 by Flagship Pioneering, Cellarity leverages powerful biological and computational technologies to perturb and quantify cellular and molecular components. This data-driven approach allows them to unlock the complexities of biology and develop drug candidates with improved translatability throughout the discovery and development process.

What sets Cellarity apart is its unique ability to view drug development through the lens of the entire cell. By targeting cellular signatures, Cellarity seeks to tackle diseases that currently lack effective treatments due to undruggable or unknown targets. Their mission is to fundamentally redesign the way drugs are created, offering new hope for patients worldwide.

Cellarity is part of the Flagship Pioneering ecosystem, which is renowned for conceiving, creating, and developing innovative bioplatform companies. With a track record of over 100 ventures and more than $100 billion in aggregate value, including Moderna, Flagship Pioneering is dedicated to transforming human health and sustainability